Real-World Use of Dostarlimab in Endometrial Cancer: A Portuguese Multicenter Study

Introduction

Dostarlimab has been available in Portugal for advanced or recurrent endometrial cancer post–platinum therapy via an early access program (EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under an early access program in June 2024. The aim of this study was to assess the efficacy and safety of dostarlimab in a Portuguese cohort of endometrial cancer patients.